EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias

Maddalena Centanni iD, Mirjam Esther van de Velde, Alwin D R Huitema, Gertjan L Kaspers iD, Mats O Karlsson iD, Lena E Friberg iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)

DOI: 10.1002/psp4.70303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 20.07.2026. Verfasst von Maddalena Centanni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Vincristine, Peripheral Nervous System Diseases, Models, Biological, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Childhood Cancer Fund, The Swedish Cancer Fund (Cancerfonden), Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vincristine is a cornerstone of pediatric chemotherapy, but its use is limited by vincristine‐induced peripheral neuropathy (VIPN). Paradoxically, African children tolerate higher vincristine doses with minimal neurotoxicity, raising questions about the pharmacological mechanisms and model generalizability across populations. In this study, we re‐estimated vincristine pharmacokinetic (PK) and PK‐pharmacodynamic (PKPD) models using data from both Dutch and Kenyan pediatric cohorts and designed five simulation scenarios to assess the impact of Type I (informative censoring) and Type II (population‐specific effect modifier) selection bias on model predictions. A three‐compartment PK model with saturable distribution and a proportional‐odds PKPD model with Markov elements jointly described vincristine disposition and VIPN risk. Kenyan children showed lower clearance but markedly reduced PD sensitivity, resulting in negligible predicted VIPN even at higher doses. Incorporating informative censoring improved internal validity by capturing the observed dropout dynamics, while mechanistic extrapolation using CYP3A5, ABCB1, and CEP72 genotype distributions increased external validity and aligned model predictions better with empirical outcomes. Clinically, these findings support population‐specific vincristine dosing strategies and suggest that reduced neurotoxicity in African children reflects lower neuronal susceptibility rather than reduced systemic (plasma) exposure. Methodologically, this work demonstrates how unrecognized selection bias can distort PKPD extrapolations across populations and highlights the value of integrating mechanistic and genetic information within model‐based frameworks to improve the safety and external validity of model‐informed dosing strategies beyond the original study populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VincristinePeripheral Nervous System DiseasesModels, BiologicalAntineoplastic Agents, PhytogenicHumansKenyaWhite PeopleCytochrome P-450 CYP3AChildATP Binding Cassette Transporter, Subfamily BSelection BiasFemaleMaleNetherlandsChild, PreschoolDose-Response Relationship, DrugGenotype

Stichwörter der Autor:innen

dosedose responseexposure responsemechanism‐based pharmacokinetics‐pharmacodynamicsmixed effect modelsnonlinear modelspediatricpharmacokinetics‐pharmacodynamicspopulation pharmacokinetics‐pharmacodynamicstoxicity

Substanzen

VincristineCytochrome P-450 CYP3AATP Binding Cassette Transporter, Subfamily BABCB1 protein, humanCYP3A5 protein, humanAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

ORCID-Profile: Maddalena Centanni, Gertjan L Kaspers, Mats O Karlsson, Lena E Friberg

Förderung

  • The Swedish Childhood Cancer Fund
  • The Swedish Cancer Fund (Cancerfonden)
  • Swedish Research Council
  • Cancerfonden
  • Vetenskapsrådet

Zitieren

APA

Centanni, M., van de Velde, M. E., Huitema, A. D. R., Kaspers, G. L., Karlsson, M. O., & Friberg, L. E. (2026). Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70303

Vancouver

Centanni M, van de Velde ME, Huitema ADR, Kaspers GL, Karlsson MO, Friberg LE. Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70303

BibTeX
@article{Centanni2026,
  author = {Centanni, Maddalena and van de Velde, Mirjam Esther and Huitema, Alwin D R and Kaspers, Gertjan L and Karlsson, Mats O and Friberg, Lena E},
  title = {Extrapolating Vincristine‐Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/psp4.70303}
}
Kostenlos starten →